October 22, 2009
By:Marissa Shapiro
Why knowing a drug's risk and preparing for a risk evaluation mitigation strategy early on will considerably benefit a drug's development.
 |
October 1, 2009
By:Peter O'Donnell
The EU struggles to get over its regulatory hurdles in an effort to further R&D success.
|
October 1, 2009
By:Juliane Carvalho, Ekopimo Ibia
The region and its regulatory agencies try to keep up with the rapidly growing clinical trials market.
|
October 1, 2009
By:Jill Wechsler
Stiffer enforcement of research standards aims to restore the public's confidence in agency actions.
|
September 1, 2009
By:Peter O'Donnell
The globalization of clinical research leads both sides of the Atlantic to collaborate on GCP inspections.
|
September 1, 2009
By:Lisa Henderson
Abuse and misuse of extended-relief opioids, get regulatory attention and potential guidance from Onsolis' REMS.
|
September 1, 2009
By:Jill Wechsler
International health crises expand testing of new vaccines and drug treatments for third-world diseases.
|
August 20, 2009
By:Michelle Perez
Taking advantage of the eCTD's cross-application feature, linking from NDA back to IND.
|
| 
